TPX2在非肌层浸润性膀胱癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.01.006

Abstract

Abstract: OBJECTIVE: To investigate expression of Xklp2 target protein (TPX2) in non-muscle-invasive bladder cancer and its clinical significance. METHODS: Data from the GEPIA database were analyzed to confirm expression of TPX2 mRNA in bladder cancer and its relationship with survival of patients. In addition,immunohistochemical staining was also used to detect the expression of TPX2 protein in 60 non-muscle-invasive bladder cancer tissues. Their relationships with clinical pathological indicator of tumors and prognosis of patients were analyzed. RESULTS: By mining the GEPIA database,TPX2 mRNA expressions were up-regulated in bladder cancer,and patients with higher expressions had lower disease-free survival rate (P<0.05). Immunohistochemical staining results showed that positive expression rate of TPX2 protein was 75% (45/60),while no positive expression was found in the corresponding basal tissues. The difference between the two groups was statistically significant (P<0.01). Expression levels of TPX2 protein were negatively correlated with clinical pathological indicators of tumors such as tumor numbers,tumor diameters,pathological grades and postoperative recurrences (P<0.05). Survival analyses showed that bladder cancer patients with higher expression of TPX2 had shorter survival time (P<0.05). CONCLUSION: Expression of TPX2 was up-regulated in bladder cancer and its expression level was negatively correlated with prognosis of patients. Therefore,it has potential to become a tumor marker for predicting prognosis in bladder cancer patients.

Key words: bladder cancer, Xklp2 target protein, clinical pathological indicator, prognosis

CLC Number:

R737.14

PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.

References

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2] ANTONI S, FERLAY J, SOERJOMATARAM I, et al. Bladder cancer incidence and mortality:a global overview and recent trends[J]. Eur Urol, 2017, 71(1):96-108.
[3] KAUFMAN D S, SHIPLEY W U, FELDMAN A S. Bladder cancer[J]. Lancet, 2009, 374(9685):239-249.
[4] BERDIK C. Unlocking bladder cancer[J]. Nature, 2017, 551(7679):S34-S35.
[5] JOHNSON S C, MCCLELLAND S E. Watching cancer cells evolve through chromosomal instability[J]. Nature, 2019, 570(7760):166-167.
[6] TIJHUIS A E, JOHNSON S C, MCCLELLAND S E. The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity[J]. Mol Cytogenet, 2019, 12:17.
[7] HEIDEBRECHT H J, BUCK F, STEINMANN J, et al. p100:a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M[J]. Blood, 1997, 90(1):226-233.
[8] VAN GIJN S E, WIERENGA E, VAN DEN TEMPEL N, et al. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells[J]. Oncogene, 2019, 38(6):852-867.
[9] ZOU J, HUANG R Y, JIANG F N, et al. Overexpression of TPX2 is associated with progression and prognosis of prostate cancer[J]. Oncol Lett, 2018, 16(3):2823-2832.
[10] GLASER Z A, LOVE H D, GUO S H, et al. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma[J]. Urol Oncol:Semin Orig Investig, 2017, 35(5):286-293.
[11] TANG Z, LI C, KANG B, et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(w1):W98-W102.
[12] SONG S M, MARU D M, AJANI J A, et al. Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma[J]. Cancer Res, 2013, 73(7):2159-2169.
[13] VICENTE J J, WORDEMAN L. The quantification and regulation of microtubule dynamics in the mitotic spindle[J]. Curr Opin Cell Biol, 2019, 60:36-43.
[14] HARRISON L E, BLEILER M, GIARDINA C. A look into centrosome abnormalities in colon cancer cells, how they arise and how they might be targeted therapeutically[J]. Biochem Pharmacol, 2018, 147:1-8.
[15] OU S R, TAN M H, WENG T, et al. LIM kinase1 regulates mitotic centrosome integrity via its activity on dynein light intermediate chains[J]. Open Biol, 2018, 8(6):170202.
[16] ALFARO-ACO R, PETRY S. How TPX2 helps microtubules branch out[J]. Cell Cycle, 2017, 16(17):1560-1561.
[17] BAYLISS R, SARDON T, VERNOS I, et al. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle[J]. Mol Cell, 2003, 12(4):851-862.
[18] LI S, LIU X, LIU T, et al. Identification of biomarkers correlated with the TNM staging and overall survival of patients with bladder cancer[J]. Front Physiol, 2017, 8:947.
[19] JIANG P Y, SHEN K X, WANG X R, et al. TPX2 regulates tumor growth in human cervical carcinoma cells[J]. Mol Med Rep, 2014, 9(6):2347-2351.
[20] ZOU Z, ZHENG B, LI J, et al. TPX2 level correlates with cholangiocarcinoma cell proliferation, apoptosis, and EMT[J]. Biomed Pharmacother, 2018, 107:1286-1293.

Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[2]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[3]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[6]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[7]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[8]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.
[9]	SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373.
[10]	TAO Yan, LI Lanlan, LU Jianzhong, LIU Shanhui, FU Shengjun, ZHANG Jing. Expression and clinical significance of FOXO3 gene in bladder cancer based on bioinformatics database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 374-379.
[11]	Lü Yanping, WU Chuancheng, YANG Shuangfeng, HE Chenzhou, HAN Renjie, YAN Wei, LIU Baoying. Relationship between differentially expressed miRNA-SNPs and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 380-386.
[12]	GUO Xiujuan, DU Yanyan, YAN Xi, ZHAO Xuetao, HAN Lina, WU Yipeng, WANG Xuexiao, MA Ming. Expression and clinical significance of CREB in esophageal squamous cell carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 387-390,394.
[13]	YANG Li, ZHANG Mengxian, ZHANG Wei, XIONG Yingyou, CHEN Shiyong, FANG Chengxiang. Data mining to investigate expression and significance of aurora kinase A in esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 221-228.
[14]	CHEN Xiuqiong, MENG Fanqiao, XIONG Hua, WANG Yali, ZHOU Yangmei, TANG Wenhua, ZOU Yanmei. Investigation and evaluation of gastric cancer core genes using bioinformatics [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 308-314.
[15]	GAO Jie, ZHANG Xiao, WEI Chao. Involvement of differentially expressed miRNA in prognosis of pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 173-179.